Company profile: Psycheceutical
1.1 - Company Overview
Company description
- Provider of patented delivery technologies for safe, bioavailable psychedelic pharmaceutical medicines, featuring NeuroDirect non-systemic topical delivery of neuro-active compounds directly into nerve tissue for immediate, sustained effects with dosage control and minimized systemic side effects, and a NeuroDirect ketamine topical in Phase I for PTSD targeting nerve endings without hallucinogenic effects.
Products and services
- Janus Particle Delivery Technology: Patented Janus particle-based platform architects advanced delivery systems to enhance safety and efficacy of psychedelic compounds for medical and pharmaceutical applications
- NeuroDirect Non-Systemic Drug Delivery Technology: Patented topical system delivers neuro-active compounds directly into nerve tissue with immediate and sustained delivery, safe dose control, and avoidance of systemic side effects
- NeuroDirect Ketamine Topical for PTSD: Phase I clinical-stage topical ketamine product targets free nerve endings at the back of the neck to deliver medication without hallucinogenic effects for PTSD treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Psycheceutical
Procemsa
HQ: Italy
Website
- Description: Provider of development, production and packaging services for food supplements, medical devices and cosmetics, supported by state-of-the-art production facilities and a Research and Development Center, offering regulatory support, clinical trial services and stability studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Procemsa company profile →
Noven Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty prescription pharmaceutical products, engaged in the research, development, manufacture, marketing and sale of these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noven Pharmaceuticals company profile →
Dyax
HQ: United States
Website
- Description: Provider of biotherapeutics focused on the discovery, development and commercialization for unmet medical needs, with an emphasis on inflammatory and oncology indications; lead product DX-88 approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dyax company profile →
Lewis and Clark Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage pharmaceutical development targeting treatments for arthritis, diabetes, glaucoma, and atherosclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lewis and Clark Pharmaceuticals company profile →
Ablynx
HQ: Belgium
Website
- Description: Provider of a proprietary Nanobody® technology platform for the discovery and development of therapeutic nanobodies—small single-domain antibody fragments—targeting serious human diseases including inflammation, haematology, oncology and pulmonary disease, with approximately 25 projects in the pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ablynx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Psycheceutical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Psycheceutical
2.2 - Growth funds investing in similar companies to Psycheceutical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Psycheceutical
4.2 - Public trading comparable groups for Psycheceutical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →